

ORIGINAL INVESTIGATION

Open Access

Vascular complications and changes in body mass index in Japanese type 2 diabetic patients with abdominal obesity

Hirofumi Nagao¹, Susumu Kashine², Hitoshi Nishizawa^{1*}, Takuya Okada³, Takekazu Kimura¹, Ayumu Hirata¹, Shiro Fukuda¹, Junji Kozawa¹, Norikazu Maeda¹, Tetsuhiro Kitamura¹, Tetsuyuki Yasuda¹, Kohei Okita¹, Toshiyuki Hibuse², Mamiko Tsugawa³, Akihisa Imagawa¹, Tohru Funahashi⁴ and Ichihiro Shimomura¹

Abstract

Background: Although many Asian type 2 diabetic patients have been considered to be not obese and have low capacity of insulin secretion, the proportion of obese patients with visceral fat accumulation has increased in recent years. We found previously considerable number of Japanese non-obese subjects (body mass index (BMI) < 25 kg/m²) with visceral fat accumulation and multiple cardiovascular risk factors. The aim of the study was to investigate the difference in clinical features of type 2 diabetic patients with and without visceral fat accumulation, focusing on vascular complications and changes in BMI.

Methods: We enrolled 88 Japanese hospitalized type 2 diabetic patients. Abdominal obesity represented waist circumference (WC) of ≥85 cm for males and ≥90 cm for females (corresponding to visceral fat area of 100 cm²). Subjects were divided into two groups; with or without abdominal obesity.

Results: Hypertension, dyslipidemia and cardiovascular diseases were significantly more in the patients with abdominal obesity. The prevalence of cardiovascular disease in the non-obese patients (BMI < 25 kg/m²) with abdominal obesity were similar in obese patients (BMI ≥25 kg/m²). The mean BMI of the patients with abdominal obesity was < 25 kg/m² at 20 years of age, but reached maximum to more than 30 kg/m² in the course. Furthermore, substantial portion of the type 2 diabetic patients (52% in males and 43% in females) were not obese at 20 year-old (BMI < 25 kg/m²), but developed abdominal obesity by the time of admission.

Conclusion: These results emphasize the need to control multiple risk factors and prevent atherosclerotic disease in patients with abdominal obesity. The significant weight gain after 20 years of age in patients with abdominal obesity stresses the importance of lifestyle modification in younger generation, to prevent potential development of type 2 diabetes and future atherosclerotic cardiovascular disease.

Keywords: Abdominal obesity, Type 2 diabetes, Waist circumference, Visceral fat accumulation, Body mass index, Cardiovascular disease

* Correspondence: hitoshin1127@endmet.med.osaka-u.ac.jp

¹Department of Metabolic Medicine, Graduate School of Medicine, Osaka University, 2-2 B-5, Yamada-oka, Suita, Osaka 565-0871, Japan
Full list of author information is available at the end of the article

Background

The prevalence of type 2 diabetes and obesity has increased worldwide, especially in Asia, in association with visceral fat accumulation [1-4]. Previous studies indicated that many Asian diabetic patients are not obese and have low capacity of insulin secretion [5-7]. However, recent evidence from some studies suggested that obesity and visceral fat accumulation were closely related to the incidence of type 2 diabetes [8-10]. Our group reported recently that obese type 2 diabetic patients secrete high insulin levels after oral glucose loading than non-obese patients [11].

Body mass index (BMI) is widely used to assess adiposity. Asians and Japanese could be easily affected with type 2 diabetes mellitus, including those with relatively low BMI compared to Caucasians [7]. Furthermore, even within the non-obese ($BMI < 25 \text{ kg/m}^2$), increase in BMI was reported to escalate the risk of type 2 diabetes mellitus in Japanese population [8]. We reported previously the identification of a considerable proportion of Japanese subjects with visceral fat accumulation (visceral fat area, $VFA \geq 100 \text{ cm}^2$) whose BMI was less than 25 kg/m^2 , and that subjects with visceral fat accumulation without overall obesity ($VFA \geq 100 \text{ cm}^2$ plus $BMI < 25 \text{ kg/m}^2$) had multiple cardiovascular risk factors [12]. There is ample evidence for the role of visceral fat accumulation in the development of multiple metabolic disorders including glucose intolerance, dyslipidemia, elevated blood pressure, and atherosclerotic cardiovascular diseases [13-20]. Collectively, these data suggest that assessment of visceral fat accumulation is useful for evaluation of high-risk group for atherosclerotic cardiovascular diseases, and also type 2 diabetes. However, to date, it has not been well characterized about the state of body weight in younger age of the current type 2 diabetic patients with visceral fat accumulation. Our group has reported previously that the mean visceral fat area increased with age after 20's in general population [21]. It may be important to know whether current type 2 patients with visceral fat accumulation has been obese or not at 20 years of age, to prevent visceral fat accumulation.

Clinically, waist circumference (WC) is used as a tool for estimation of VFA. In Japanese population, VFA of 100 cm^2 has been demonstrated to correspond approximately to WC of 85 cm in male and 90 cm in female [21,22]. Therefore, in Japanese guidelines for the metabolic syndrome, WC is used as an index of visceral fat accumulation for practical convenience [23].

The aim of this study is to investigate the difference in clinical features of type 2 diabetic patients with or without abdominal obesity ($WC \geq 85 \text{ cm}$ in males, $\geq 90 \text{ cm}$ in females), with a special focus on vascular complications and changes in BMI.

Methods

Subjects

The study subjects were 88 Japanese type 2 diabetic patients who had been hospitalized because of poor glycemic control and/or the staging of complications at three institutions: Department of Endocrinology and Metabolism in Osaka University Hospital during the period from January 2010 to December 2010 (consecutive 54 patients were enrolled), Ikeda Municipal Hospital during the period from July 2011 to December 2011 (consecutive 16 patients were enrolled), Suita Municipal Hospital during the period from August 2011 to March 2012 (consecutive 18 patients were enrolled). The Medical Ethics Committee of Osaka University approved the study. Each participant gave a written informed consent.

Type 2 diabetes was defined according to the World Health Organization (WHO) National diabetic group criteria of 2006 and/or treatment of diabetes. The following patients were excluded, (1) patients in whom WC was not measured, (2) patients who were younger than 40 years or older than 64 years on admission, (3) patients who were diagnosed with type 1 diabetes mellitus, (4) patients positive for anti-GAD antibody, (5) patients who did not attend the diabetes education course due to severity of their illness.

Clinical examination

Body weight at 20 years of age and maximum body weight were retrieved through medical interview. The duration of diabetes and the number of hospitalizations were determined from the medical interview and medical records. Second-degree family history of diabetes was obtained from every patient. Height (cm), weight (kg) and WC at umbilical level (cm) were measured in the standing position on admission. Diabetic retinopathy was assessed by an ophthalmologist. The stages of diabetic nephropathy were classified as normoalbuminuria [urinary albumin-creatinine ratio (UACR): $< 30 \text{ mg/g}$ creatinine], microalbuminuria (UACR $30\text{--}299 \text{ mg/g}$ creatinine) and overt proteinuria (UACR: $\geq 300 \text{ mg/g}$ creatinine). Venous blood samples were collected after overnight fasting for measurement of high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, triglyceride, insulin, C-peptide, creatinine and HbA1c (Japan Diabetes Society, JDS). The value for HbA1c (%) was estimated as National Glycohemoglobin Standardization Program (NGSP) equivalent value (%), calculated by the formula $HbA1c (\%) = 1.02 \times HbA1c(JDS) + 0.25$ [24]. The homeostasis model assessment of insulin resistance ($HOMA-IR = \text{fasting plasma glucose (mg/dL)} \times \text{fasting immunoreactive insulin } (\mu\text{U/mL}) / 405$) was evaluated after achieving fair glycemic control (fasting plasma glucose $< 140 \text{ mg/dL}$ [25]), but patients

treated with insulin were excluded. The maximum intima-media thickness (IMT) of the carotid artery was measured in supine position by echography. Maximum carotid IMT was measured on both the right and left sides in the observation-possible areas of the common carotid artery, bulbous, and internal carotid artery, but not the external carotid artery.

Definition of abdominal obesity, hypertension, dyslipidemia and cardiovascular disease

Abdominal obesity was assessed WC of ≥ 85 cm for males and ≥ 90 cm for females [21,22]. Hypertension was defined as systolic blood pressure of ≥ 140 mmHg and/or diastolic blood pressure of ≥ 90 mmHg. Dyslipidemia was defined as low-density lipoprotein cholesterol concentration of >140 mg/dL and/or triglyceride concentration of >150 mg/dL and/or high-density lipoprotein cholesterol concentration of <40 mg/dL. If patients received anti-hypertensive and /or anti-lipidemic medications, they were considered positive for hypertension and /or dyslipidemia. Cardiovascular disease was defined as coronary artery disease (CAD) and/or cerebrovascular disease and/or peripheral arterial disease (PAD). CAD was defined as significant coronary stenosis(es) by coronary angiography or computed tomography, and/or positive ischemia by stress myocardial scintigraphy. Cerebrovascular disease was defined as history of stroke by a medical interview and/or old cerebral infarction by magnetic resonance imaging (MRI). PAD was defined as ankle-brachial index (ABI) ≤ 0.9 or performance of a revascularization procedure or amputation of lower extremity because of PAD [26,27].

Statistical analysis

All values were expressed as mean \pm SD. In all cases, probability (P) values of <0.05 were considered statistically significant. We performed unpaired *t*-test to determine the difference in various parameters between two groups (Table 1). Frequencies were compared between two groups by the Fisher's exact test (Table 1, Figures 1). Changes in BMI in the same group were analyzed by paired *t*-test (Figure 2). Cochran-Armitage trend test was used to analyze the relationship between two groups of diabetic retinopathy and diabetic nephropathy (Table 1). All analyses were conducted by using the JMP version 9.0.2 for Windows (SAS Institute, Cary, NC).

Results

Characteristics of participants

We enrolled 88 Japanese patients in this study (51 men and 37 women; age, 55.1 ± 7.1 years [mean \pm SD]; range, 40–64 years, BMI 26.2 ± 5.5 kg/m², WC; males 91.4 ± 9.8 cm, females 91.8 ± 13.4 cm). We divided the patients into two groups by WC. Abdominal obesity was defined as

WC ≥ 85 cm in males, WC ≥ 90 cm in females [19]. Patients with smaller WC formed the abdominal obesity (–) group. Table 1 summarizes the profiles of the 60 patients (68%) of the abdominal obesity (+) group and 28 patients (32%) of the abdominal obesity (–) group. There were no significant differences in age, duration of diabetes, family history of diabetes, HbA1c, fasting plasma glucose and maximum carotid IMT between the two groups. Furthermore, there were no significant differences in the percentage of patients with microangiopathies (diabetic retinopathy and diabetic nephropathy) between the two groups. On the other hand, BMI, fasting insulin, fasting C-peptide and HOMA-IR of the abdominal obesity (+) group were higher than those of the abdominal obesity (–) group.

Clinical features of type 2 diabetic patients with abdominal obesity

Hypertension and dyslipidemia were significantly more common in the abdominal obesity (+) group compared with the abdominal obesity (–) group (68% vs 29% and 79% vs 57%, respectively, Figure 1A). Prevalence of cardiovascular diseases was higher in the abdominal obesity (+) group than the abdominal obesity (–) group (22% vs 4%, respectively, $p < 0.05$). Cardiovascular diseases in detail as follows; CAD 8 cases (7 cases in abdominal obesity (+) group and 1 case in abdominal obesity (–) group; cerebrovascular disease 4 cases (abdominal obesity (+) group); and PAD 4 cases (abdominal obesity (+) group). Two patients with abdominal obesity suffered from two cardiovascular diseases, respectively (CAD + PAD and cerebrovascular disease + PAD).

Next, we investigated the relationship between prevalence of cardiovascular disease and body fat distribution. Subjects were divided according to their BMI and WC (Figure 1B). Among 88 patients, 50 patients (57%) were obese (BMI ≥ 25 kg/m²) with abdominal obesity. Among the non-obese (BMI < 25 kg/m²) patients, abdominal obesity was common (10/38: 26%) and the prevalence of cardiovascular disease was significantly higher, compared with the abdominal obesity (–) group. The prevalence of cardiovascular disease in non-obese (BMI < 25 kg/m²) patients with abdominal obesity was similar to that in obese (BMI ≥ 25 kg/m²) patients.

Changes in BMI after 20 years of age in type 2 diabetics with abdominal obesity

We compared body weight at 20 years of age, at maximum and at admission to clarify changes in BMI in diabetic patients with and without abdominal obesity (Figure 2). The body weight at 20 years of age and the maximum weight were obtained at the medical interview. The mean BMI of the abdominal obesity (–) group was < 25 kg/m² at 20 years of age, at maximum and at

Table 1 Baseline characteristics

	Abdominal obesity		p value
	(-) group	(+) group	
n	28	60	
Males/Females	13/15	38/22	0.167
Age, years	55.7 ± 6.7	54.8 ± 7.3	0.575
Body mass index, kg/m ²	20.9 ± 2.3	28.7 ± 4.8	<0.01
Duration of diabetes mellitus, years	11.6 ± 10.3	9.1 ± 7.8	0.216
Number of hospitalizations	1.7 ± 0.9	2.3 ± 2.0	0.176
Family history of diabetes mellitus, %	61	53	0.646
Fasting plasma glucose, mg/dL	154 ± 56	153 ± 50	0.951
Hemoglobin A1c (NGSP), % (mmol/mol)	9.3 ± 2.2 (78)	9.1 ± 1.9 (76)	0.648
Fasting insulin, IU/L	4.6 ± 2.9	9.9 ± 8.4	<0.01
Fasting C-peptide, ng/mL	1.5 ± 0.9	2.0 ± 1.0	<0.05
HOMA-IR	1.5 ± 1.0 (n = 18)	3.4 ± 3.5 (n = 30)	<0.05
Maximum carotid IMT, mm	1.4 ± 0.7	1.6 ± 1.0	0.345
Diabetic retinopathy (NDR/SDR/PPDR/PDR)	16/5/0/7	41/7/3/8	0.250
Diabetic nephropathy (normo/micro/overt)	21/5/2	44/9/6	0.814
Discharge medications for diabetes mellitus			
Sulfonylurea, %	32	20	0.283
Biguanide, %	7	40	<0.01
Thiazolidinedione, %	14	12	0.738
Alpha-glucosidase inhibitor, %	18	15	0.760
Glinide, %	0	5	0.548
Dipeptidyl peptidase-4 inhibitor, %	18	27	0.431
Glucagon-like peptide-1 analog, %	0	8	0.173
Insulin, %	54	38	0.248

Data are mean ± SD, number of subjects or frequency [n (%)]. NGSP national glycohemoglobin standardization program, HOMA-IR homeostasis model assessment of insulin resistance, IMT intima-media thickness, NDR non-diabetic retinopathy, SDR simple diabetic retinopathy, PPDR preproliferative diabetic retinopathy, PDR proliferative diabetic retinopathy, normo normoalbuminuria, micro microalbuminuria, overt overt proteinuria.

admission. On the other hand, the mean BMI of the abdominal obesity (+) group was 23.5 kg/m² at 20 years of age (non-obese), but reached maximum to more than 30 kg/m² in the course. The BMI at 20 years of age was significantly higher in the abdominal obesity (+) group than in the abdominal obesity (-) group (23.5 kg/m² vs 20.7 kg/m², respectively).

Finally, we examined the relationship between WC at admission and BMI at 20 years of age in all subjects with type 2 diabetes (Figure 3). 52% (n = 25) in males and 43% (n = 15) in females of the type 2 diabetic patients were not obese at 20 year-old (BMI < 25 kg/m²), but developed abdominal obesity by the time of admission.

Discussion

The purpose of this cross-sectional study was to clarify the clinical features of type 2 diabetic patients with abdominal obesity. In the present study, we demonstrated the following differences between the abdominal obesity (+)

group and the abdominal obesity (-) group; 1) Hypertension and dyslipidemia were significantly more prevalent in type 2 diabetic patients with abdominal obesity. 2) Cardiovascular diseases were significantly more in patients with abdominal obesity. 3) There were no significant differences in the prevalence of diabetic microangiopathies (diabetic retinopathy and diabetic nephropathy) between the two groups. 4) In the abdominal obesity (+) group, the mean BMI was < 25 kg/m² at 20 years of age (non-obese), but reached maximum to more than 30 kg/m² in the course. 5) Substantial portion of the type 2 diabetic patients (52% in males and 43% in females) were not obese at 20 year-old (BMI < 25 kg/m²), but developed abdominal obesity by the time of admission.

Abdominal obesity and atherosclerotic cardiovascular disease

Visceral fat accumulation is accompanied by lifestyle changes, such as disturbance of eating habits, physical




Figure 1 Metabolic risk factors and cardiovascular disease in type 2 diabetic patients with abdominal obesity. **(A)** Prevalence of hypertension, dyslipidemia and cardiovascular disease in type 2 diabetic patients with abdominal obesity. **(B)** Relationship between prevalence of cardiovascular disease and body fat distribution. Subjects were divided according to body mass index (BMI) and waist circumference (WC). Abdominal obesity represented WC of ≥ 85 cm in males and ≥ 90 cm in females. * $P < 0.05$, ** $P < 0.01$.

inactivity and sleep disorders. The hypertrophied adipocytes in intra-abdominal visceral fat exhibit hyperlipolytic activity, which is resistant to the antilipolytic effect of insulin [28,29]. The resulting hyper-free-fatty-acidemia and hyperglycerolemia in the portal vein increase the production of triacylglycerol-rich lipoproteins [30-33] and glucose in the liver [34,35], leading to dyslipidemia, insulin resistance and diabetes. Adipose tissue is not only an energy-storage organ, but it produces and secretes a variety of biologically active molecules known as adipocytokines, such as adiponectin, PAI-1 and TNF- α [15,16,36,37]. Dysregulation of adipocytokines caused by visceral fat accumulation is regarded as one of the major pathophysiological mechanisms of atherosclerosis associated with the metabolic syndrome. Our group has demonstrated that some of anti-diabetic, anti-hypertensive, and anti-dyslipidemic agents had potential to target obesity and hypoadiponectinemia [38-42].

In Japanese guidelines for the metabolic syndrome, WC is used as an index of visceral fat accumulation for practical convenience [23]. Metabolic syndrome is defined as those having visceral fat accumulation expressed by increased WC (WC ≥ 85 cm in males, ≥ 90 cm in females) and 2 or more risk factors [23]. In the present study, abdominal obesity was defined as WC ≥ 85 cm in males and WC ≥ 90 cm in females. Thus, visceral fat accumulation is suspected to be present in type 2 diabetic patients with abdominal obesity. Hypertension, dyslipidemia and cardiovascular disease were significantly more in type 2 diabetic patients with abdominal obesity than patients without such obesity. To prevent atherosclerotic cardiovascular disease (diabetic macroangiopathy), it is necessary to search thoroughly for atherosclerotic cardiovascular disease in type 2 diabetes patients with abdominal obesity. On the other hand, there were no significant differences in the prevalence of




Figure 2 Changes in BMI after 20 years of age in type 2 diabetic patients. Data are mean ± SD. **P < 0.01.

diabetic microangiopathies (diabetic retinopathy and diabetic nephropathy) between the two groups, suggesting that it is necessary to rule out the presence of microangiopathy in all patients with type 2 diabetes, regardless of abdominal obesity. Recent reports have demonstrated that the development and progression of diabetic microangiopathy is influenced by glycemic control and duration of diabetes [43-46], suggesting that it is necessary to search thoroughly for diabetic microangiopathy in the patients with poor glycemic control and/or long duration of diabetes.

In our study of Japanese male urban workers [12], visceral fat accumulation (VFA ≥ 100 cm²) was observed in a relatively large proportion of patients with BMI < 25 kg/m² (non-obese) (26.8%). In the same study, we have

demonstrated the presence of multiple risk factors in such subjects [12]. From the viewpoint of abdominal obesity (estimation of VFA from WC), we divided the participants in the present study (type 2 diabetics) into four groups according to BMI and presence of abdominal obesity (Figure 1B), and demonstrated the relationship of adiposity with the prevalence of cardiovascular disease. Abdominal obesity was recognized in all patients with BMI ≥ 25 kg/m², and observed in relatively large numbers (n = 10: 26%) of non-obese patients (BMI < 25 kg/m²). The prevalence of cardiovascular disease in such patients with abdominal obesity (+) plus BMI < 25 kg/m² was similar to that in obese patients (BMI ≥ 25 kg/m²), and significantly higher than in patients without abdominal obesity and BMI < 25 kg/m². These results suggest that WC,




Figure 3 Relationship between WC at admission and BMI at 20 years of age in (A) males (B) females.

which reflects visceral fat accumulation, is more useful for evaluation of the risk of cardiovascular disease in type 2 diabetic patients, compared with BMI. The present study also suggests that measurement of WC should be more important in patients with BMI < 25 kg/m² (non-obese) for the prevention of clustering of multiple risk factors and cardiovascular disease, because all patients with BMI ≥25 kg/m² had abdominal obesity.

Weight gain after 20 years of age in type 2 diabetic patients with abdominal obesity

We analyzed body weight at 20 years of age and at maximum obtained through medical interview, and determined the changes in BMI in type 2 diabetic patients with abdominal obesity. Interestingly, the mean BMI was < 25 kg/m² at 20 years of age (non-obese), but reached maximum to more than 30 kg/m² in the course (Figure 2). Substantial portion of the type 2 diabetic patients (52% in males and 43% in females) were not obese at 20 year-old (BMI < 25 kg/m²), but developed abdominal obesity by the time of admission (Figure 3), suggesting that environmental factors, such as disturbance of eating habits, physical inactivity and sleep disorders, affected visceral fat accumulation after 20 years of age in these patients.

Recent researches reported that subjects with abdominal obesity were more likely to develop diabetes for five years and had higher mortality within after 13 years than those without abdominal obesity [47,48]. Considered together, our results suggest that intervention to individuals with abdominal obesity such as health education and health guidance after health checkup should be important in reducing the risk of future diabetes and cardiovascular disease after 20 years of age. Our results also showed that the mean BMI at 20 years of age was already higher in the abdominal obesity (+) group than in the abdominal obesity (-) group, suggesting that early intervention such as health education and diet control during childhood and adolescence at school and home is important to reduce the risk of future cardiovascular diseases.

The present study has several limitations. The study was not prospective in design, and included a relatively small population limited to Japanese, who have different physique from Caucasians.

Conclusions

The present study demonstrated higher prevalence of hypertension, dyslipidemia and cardiovascular disease among type 2 diabetic patients with abdominal obesity and probable visceral fat accumulation compared to those without abdominal obesity. Furthermore, significant weight gain was observed in type 2 diabetic patients with abdominal obesity after 20 years of age. These

results suggest that education on lifestyle modification in younger generation, to prevent visceral fat accumulation is important for the prevention of type 2 diabetes and future atherosclerotic cardiovascular disease.

Consent

Written informed consent was obtained from the patient for the publication of this report and any accompanying images.

Abbreviations

ABI: Ankle-brachial index; BMI: Body mass index; CAD: Coronary artery disease; HOMA-IR: The homeostasis model assessment of insulin resistance; IMT: Intima-media thickness; JDS: Japan Diabetes Society; MRI: Magnetic resonance imaging; NGSP: National Glycohemoglobin Standardization Program; PAD: Peripheral arterial disease; UACR: The urinary albumin-creatinine ratio; VFA: Visceral fat area; WC: Waist circumference; WHO: World Health Organization.

Competing interests

The authors declare no conflict of interest.

Authors' contributions

HN and SK acquired and analyzed data, and wrote the manuscript. HN conceived study, analyzed data, and wrote the manuscript. TO, TK, AH, SF, JK, NM, TK, TY, KO, TH, MT, and AI acquired and researched data. TF and IS reviewed the manuscript. All authors read and approved the final manuscript.

Acknowledgements

We thank all members of the Adiposcience Laboratory at the Department of Metabolic Medicine, Graduate School of Medicine, Osaka University for the helpful discussion and suggestions. We also thank Rie Suga and Keiko Irishio from the Department of Clinical Research, Ikeda Municipal Hospital, for data acquisition. This work was supported in part by Grants-in-Aid for Scientific Research (C) no. 24591351 (to HN), and no. 22590979 (to NM), Scientific Research on Innovative Areas no. 22126008 (to TF), and Pfizer Health Research Foundation (to HN).

Author details

¹Department of Metabolic Medicine, Graduate School of Medicine, Osaka University, 2-2 B-5, Yamada-oka, Suita, Osaka 565-0871, Japan. ²Suita Municipal Hospital, 2-13-20, Katayamacho, Suita, Osaka 564-0082, Japan. ³Ikeda Municipal Hospital, 3-1-18, Jonan, Ikeda, Osaka 563-8510, Japan. ⁴Department of Metabolism and Atherosclerosis, Graduate School of Medicine, Osaka University, 2-2-B, Yamada-oka, Suita, Osaka 565-0871, Japan.

Received: 30 April 2013 Accepted: 13 June 2013

Published: 18 June 2013

References

1. World Health Organization: *Obesity and overweight; WHO Fact Sheet No311*; 2013. <http://www.who.int/mediacentre/factsheets/fs311/en/index.html>.
2. Shaw JE, Sicree RA, Zimmet PZ: **Global estimates of the prevalence of diabetes for 2010 and 2030.** *Diabetes Res Clin Pract* 2010, **87**:4-14.
3. Yoon KH, Lee JH, Kim JW, Cho JH, Choi YH, Ko SH, Zimmet P, Son HY: **Epidemic obesity and type 2 diabetes in Asia.** *Lancet* 2006, **368**:1681-1688.
4. Chan JC, Malik V, Jia W, Kadowaki T, Yajnik CS, Yoon KH, Hu FB: **Diabetes in Asia. epidemiology, risk factors, and pathophysiology.** *JAMA* 2009, **301**:2129-2140.
5. Fujimoto WY: **Overview of non-insulin-dependent diabetes mellitus (NIDDM) in different population groups.** *Diabet Med* 1996, **13**:S7-S10.
6. Fujimoto WY, Akanuma Y, Kanazawa Y, Mashiko S, Leonetti D, Wahl P: **Plasma insulin levels in Japanese and Japanese-American men with type 2 diabetes may be related to the occurrence of cardiovascular disease.** *Diabetes Res Clin Pract* 1989, **6**:121-127.
7. Huxley R, James WP, Barzi F, Patel JV, Lear SA, Suriyawongpaisal P, Janus E, Catterson I, Zimmet P, Prabhakaran D, Reddy S, Woodward M: **Obesity in**

- Asia Collaboration. Ethnic comparisons of the cross-sectional relationships between measures of body size with diabetes and hypertension. *Obes Rev* 2008, **9**:53–61.
8. Nagaya T, Yoshida H, Takahashi H, Kawai M: **Increases in body mass index, even within non-obese levels, raise the risk for Type 2 diabetes mellitus: a follow-up study in a Japanese population.** *Diabet Med* 2005, **22**:1107–1111.
 9. Oh SW, Shin SA, Yun YH, Yoo T, Huh BY: **Cut-off point of BMI and obesity-related comorbidities and mortality in middle-aged Koreans.** *Obes Res* 2004, **12**:2031–2040.
 10. Neeland IJ, Ayers CR, Rohatgi AK, Turer AT, Berry JD, Das SR, Vega GL, Khera A, McGuire DK, Grundy SM, de Lemos JA: **Associations of visceral and abdominal subcutaneous adipose tissue with markers of cardiac and metabolic risk in obese adults.** *Obesity (Silver Spring)* 2012. doi:10.1002/oby.20135. Epub ahead of print.
 11. Iwahashi H, Okauchi Y, Ryo M, Noguchi M, Morita S, Kishida K, Okita K, Ohira T, Funahashi T, Nakamura T, Imagawa A, Shimomura I: **Insulin-secretion capacity in normal glucose tolerance, impaired glucose tolerance, and diabetes in obese and non-obese Japanese patients.** *J Diabetes Invest* 2012, **3**:271–275.
 12. Okauchi Y, Nishizawa H, Funahashi T, Ogawa T, Noguchi M, Ryo M, Kihara S, Iwahashi H, Yamagata K, Nakamura T, Shimomura I, Matsuzawa Y: **Reduction of visceral fat is associated with decrease in the number of metabolic risk factors in Japanese men.** *Diabetes Care* 2007, **30**:2392–2394.
 13. Kissebah AH, Wydelingum N, Murray R, Evans DJ, Hartz AJ, Kalkhoff RK, Adams PW: **Relation of body fat distribution to metabolic complications of obesity.** *J Clin Endocrinol Metab* 1982, **54**:254–260.
 14. Nakamura T, Tokunaga K, Shimomura I, Nakamura T, Tokunaga K, Shimomura I, Nishida M, Yoshida S, Kotani K, Islam AH, Keno Y, Kobatake T, Nagai Y, Fujioka S, Tarui S, Matsuzawa Y: **Contribution of visceral fat accumulation to the development of coronary artery disease in non-obese men.** *Atherosclerosis* 1994, **107**:239–246.
 15. Shimomura I, Funahashi T, Takahashi M, Maeda K, Kotani K, Nakamura T, Yamashita S, Miura M, Fukuda Y, Takemura K, Tokunaga K, Matsuzawa Y: **Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity.** *Nat Med* 1996, **2**:800–803.
 16. Hotmislighi GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM: **Increased adipose tissue expression of tumor necrosis factor- α in human obesity and insulin resistance.** *J Clin Invest* 1995, **95**:2409–2415.
 17. Lindsay RS, Funahashi T, Hanson RL, Matsuzawa Y, Tanaka S, Tataranni PA, Knowler WC, Krakoff J: **Adiponectin and development of type 2 diabetes in the Pima Indian population.** *Lancet* 2002, **360**:57–58.
 18. Ryo M, Nakamura T, Kihara S, Kumada M, Shibazaki S, Takahashi M, Nagai M, Matsuzawa Y, Funahashi T: **Adiponectin as a biomarker of the metabolic syndrome.** *Circ J* 2004, **68**:975–981.
 19. Mallamaci F, Zoccali C, Cuzzola F, Tripepi G, Cutrupi S, Parlongo S, Tanaka S, Ouchi N, Kihara S, Funahashi T, Matsuzawa Y: **Adiponectin in essential hypertension.** *J Nephrol* 2002, **15**:507–511.
 20. Mohammadreza B, Farzad H, Davoud K, Fereidoun Prof AF: **Prognostic significance of the complex "Visceral Adiposity Index" vs. simple anthropometric measures: Tehran lipid and glucose study.** *Cardiovasc Diabetol* 2012:11–20.
 21. Hiuge-Shimizu A, Kishida K, Funahashi T, Ishizaka Y, Oka R, Okada M, Suzuki S, Takaya N, Nakagawa T, Fukui T, Fukuda H, Watanabe N, Yoshizumi T, Nakamura T, Matsuzawa Y, Yamakado M, Shimomura I: **Absolute value of visceral fat area measured on computed tomography scans and obesity-related cardiovascular risk factors in large-scale Japanese general population (the VACATION-J study).** *Ann Med* 2012, **44**:82–92.
 22. New criteria for 'obesity disease' in Japan. Examination Committee of Criteria for 'Obesity Disease' in Japan; Japan Society for the Study of Obesity: **New criteria for 'obesity disease' in Japan. Examination Committee of Criteria for 'Obesity Disease' in Japan.** *Circ J* 2002, **66**:987–992.
 23. Teramoto T, Sasaki J, Ueshima H, Egusa G, Kinoshita M, Shimamoto K, Daida H, Biro S, Hirobe K, Funahashi T, Yokote K, Yokode M: **Metabolic syndrome.** *J Atheroscler Thromb* 2008, **15**:1–5.
 24. Kashiwagi A, Kasuga M, Araki E, Oka Y, Hanafusa T, Ito H, Tominaga M, Oikawa S, Noda M, Kawamura T, Sanke T, Namba M, Hashiramoto M, Sasahara T, Nishio Y, Kuwa K, Ueki K, Takei I, Umemoto M, Murakami M, Yamakado M, Yatomi Y, Ohashi H: **International clinical harmonization of glycated hemoglobin in Japan : From Japan Diabetes Society to National Glycohemoglobin Standardization Program values.** *J Diabetes Invest* 2012, **3**:39–40.
 25. Yki-Järvinen H, Esko N, Eero H, Marja-Riitta T: **Clinical benefits and mechanisms of a sustained response to intermittent insulin therapy in type 2 diabetic patients with secondary drug failure.** *Am J Med* 1988, **84**:185–92.
 26. Hiatt WR: **Medical Treatment of Peripheral Arterial Disease and Claudication.** *N Engl J Med* 2001, **344**:1608–1621.
 27. Mohler ER 3rd: **Peripheral arterial disease: identification and implications.** *Arch Intern Med* 2003, **163**:2306–2314.
 28. Smith U, Hammersten J, Björntorp P, Kral JG: **Regional differences and effect of weight reduction on human fat cell metabolism.** *Eur J Clin Invest* 1979, **9**:327–332.
 29. Mittelman SD, Van Citters GW, Kirkman EL, Bergman RN: **Extreme insulin resistance of the central adipose depot in vivo.** *Diabetes* 2002, **51**:755–761.
 30. Londo C, Brasaemle DL, Schultz CJ, Adler-Wailes DC, Levin DM, Kimmel AR, Rondinone CM: **On the control of lipolysis in adipocytes.** *Ann N Y Acad Sci* 1999, **892**:155–168.
 31. Kuriyama H, Yamashita S, Shimomura I, Funahashi T, Ishigami M, Aragane K, Miyaoka K, Nakamura T, Takemura K, Man Z, Toide K, Nakayama N, Fukuda Y, Lin MC, Wetterau JR, Matsuzawa Y: **Enhanced expression of hepatic acyl-coenzyme A synthetase and microsomal triglyceride transfer protein messenger RNAs in the obese and hypertriglyceridemic rat with visceral fat accumulation.** *Hepatology* 1998, **27**:557–562.
 32. White DA, Bennett AJ, Billett MA, Salter AM: **The assembly of triacylglycerol-rich lipoproteins: an essential role for the microsomal triacylglycerol transfer protein.** *Br J Nutr* 1998, **80**:219–229.
 33. Adeli K, Taghibiglou C, Van Iderstine SC, Lewis GF: **Mechanisms of hepatic very low-density lipoprotein overproduction in insulin resistance.** *Trends Cardiovasc Med* 2001, **11**:170–176.
 34. Kuriyama H, Shimomura I, Kishida K, Kondo H, Furuyama N, Nishizawa H, Maeda N, Matsuda M, Nagaretani H, Kihara S, Nakamura T, Tochino Y, Funahashi T, Matsuzawa Y: **Coordinated regulation of fat-specific and liver-specific glycerol channels, aquaporin adipose and aquaporin 9.** *Diabetes* 2002, **51**:2915–2921.
 35. Maeda N, Funahashi T, Shimomura I: **Metabolic impact of adipose and hepatic glycerol channels aquaporin 7 and aquaporin 9.** *Nat Clin Pract Endocrinol Metab* 2008, **4**:627–34.
 36. Spiegelman BM, Flier JS: **Obesity and the regulation of energy balance.** *Cell* 2001, **23**:531–543.
 37. Matsuzawa Y, Funahashi T, Nakamura T: **The concept of metabolic syndrome: contribution of visceral fat accumulation and its molecular mechanism.** *J Atheroscler Thromb* 2011, **18**:629–639.
 38. Maeda N, Takahashi M, Funahashi T, Kihara S, Nishizawa H, Kishida K, Nagaretani H, Matsuda M, Komuro R, Ouchi N, Kuriyama H, Hotta K, Nakamura T, Shimomura I, Matsuzawa Y: **PPAR γ ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein.** *Diabetes* 2001, **50**:2094–2099.
 39. Kurata A, Nishizawa H, Kihara S, Maeda N, Sonoda M, Okada T, Ohashi K, Hibuse T, Fujita K, Yasui A, Hiuge A, Kumada M, Kuriyama H, Shimomura I, Funahashi T: **Blockade of Angiotensin II type-1 receptor reduces oxidative stress in adipose tissue and ameliorates adipocytokine dysregulation.** *Kidney Int* 2006, **70**:1717–1724.
 40. Hiuge A, Tenenbaum A, Maeda N, Benderly M, Kumada M, Fisman EZ, Tanne D, Matas Z, Hibuse T, Fujita K, Nishizawa H, Adler Y, Motro M, Kihara S, Shimomura I, Behar S, Funahashi T: **Effects of peroxisome proliferator-activated receptor ligands, bezafibrate and fenofibrate, on adiponectin level.** *Arterioscler Thromb Vasc Biol* 2007, **27**:635–641.
 41. Inoue K, Maeda N, Kashine S, Fujishima Y, Kozawa J, Hiuge-Shimizu A, Okita K, Imagawa A, Funahashi T, Shimomura I: **Short-term effects of liraglutide on visceral fat adiposity, appetite, and food preference: a pilot study of obese Japanese patients with type 2 diabetes.** *Cardiovasc Diabetol* 2011, **10**:109.
 42. Fujishima Y, Maeda N, Inoue K, Kashine S, Nishizawa H, Hirata A, Kozawa J, Yasuda T, Okita K, Imagawa A, Funahashi T, Shimomura I: **Efficacy of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight, eating behavior, and glycemic control, in Japanese obese type 2 diabetes.** *Cardiovasc Diabetol* 2012, **11**:107.
 43. Yoshida Y, Hagura R, Hara Y, Sugasawa G, Akanuma Y: **Risk factors for the development of diabetic retinopathy in Japanese type 2 diabetic patients.** *Diabetes Res Clin Pract* 2001, **51**:195–203.

44. Stratton IM, Kohner EM, Aldington SJ, Turner RC, Holman RR, Manley SE, Matthews DR, UKPDS 50: risk factors for incidence and progression of retinopathy in Type II diabetes over 6 years from diagnosis. *Diabetologia* 2001, **44**:156–163.
45. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. *N Engl J Med* 1993, **329**:977–986.
46. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). *Lancet* 1998, **352**:837–853.
47. Lee IT, Chiu YF, Hwu CM, He CT, Chiang FT, Lin YC, Assimes T, Curb JD, Sheu WH: Central obesity is important but not essential component of the metabolic syndrome for predicting diabetes mellitus in a hypertensive family-based cohort. Results from the Stanford Asia-pacific program for hypertension and insulin resistance (SAPHIRE) Taiwan follow-up study. *Cardiovasc Diabetol* 2012, **11**:43.
48. van der A DL, Nooyens AC, van Duijnhoven FJ, Verschuren WM, Boer JM: All-cause mortality risk of metabolically healthy abdominal obese individuals: The EPIC-MORGEN study. *Obesity (Silver Spring)* 2013. doi:10.1002/oby.20480. Epub ahead of print.

doi:10.1186/1475-2840-12-88

Cite this article as: Nagao *et al.*: Vascular complications and changes in body mass index in Japanese type 2 diabetic patients with abdominal obesity. *Cardiovascular Diabetology* 2013 **12**:88.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

